Nama's AI scorecard currently rates Alcon Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ALC's P/E ratio?

Alcon trades at a trailing price-to-earnings ratio of 23.0.

When does ALC report earnings?

Alcon's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.89.

What is the ALC price target?

The median analyst price target from 16 analysts is $81.50, with a range of $62.00 – $103.00.

Is ALC Shariah compliant?

Nama's AAOIFI-style screen reads Alcon as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does ALC pay a dividend?

Yes — Alcon's dividend yield is 0.5%.

Nama Insights

Alcon (ALC)

Healthcare · Medical Instruments Supplies · NYSE

Alcon (ALC) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $36.23B, a trailing price-to-earnings ratio of 23.0 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 4.9% and free cash flow per share grew 14.6%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -15.2% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-25.9%

How far the last close sits under the highest price of the past five years.

Market cap	$36.23B
Trailing P/E	23.0
Price / book	1.7
Price / sales	3.3
FCF yield	4.3%
Dividend yield	0.5%
Gross margin	56.9%
Operating margin	8.7%
Net margin	5.9%
Revenue growth (YoY)	+4.9%
Revenue growth (3-yr annual)	+6.1%
EPS growth (YoY)	+0.3%
FCF/share growth (YoY)	+14.6%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

ALC earnings

Next report: Nov 10, 2026 (Q3 2026, EPS estimate $0.89). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	$0.84	$0.76	+10.5%	$2.82B
Q1 2026	May 5, 2026	$0.85	$0.82	+3.7%	$2.71B
Q4 2025	Feb 24, 2026	$0.78	$0.79	-1.3%	$2.72B
Q3 2025	Nov 11, 2025	$0.79	$0.77	+2.6%	$2.61B

ALC analyst price target

Median target $81.50 from 16 analysts, ranging $62.00 – $103.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3
COO	Cooper Companies	$11.86B	13.5

Explore live ALC data on Nama Insights →

Recent Congressional trades

Alcon trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Josh Gottheimer	House	Sell	$1,001 - $15,000	Apr 8, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Apr 14, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024
Daniel Goldman	House	Sell	$15,001 - $50,000	Aug 13, 2023

ALC FAQ

Is ALC a buy?: Nama's AI scorecard currently rates Alcon Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ALC's P/E ratio?: Alcon trades at a trailing price-to-earnings ratio of 23.0.
When does ALC report earnings?: Alcon's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.89.
What is the ALC price target?: The median analyst price target from 16 analysts is $81.50, with a range of $62.00 – $103.00.
Is ALC Shariah compliant?: Nama's AAOIFI-style screen reads Alcon as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does ALC pay a dividend?: Yes — Alcon's dividend yield is 0.5%.